Acute myeloid leukemia: Therapeutic impact of epigenetic drugs
Authors:
- Lucia AltucciLucia Altucci
- Nicole ClarkeNCNicole Clarke
- Angela NebbiosoANAngela Nebbioso
- Annamaria ScognamiglioASAnnamaria Scognamiglio
- Hinrich GronemeyerHGHinrich Gronemeyer
- 1 September 2005
- journal article
- review article
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 37 (9) , 1752-1762
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Histone deacetylase inhibitors – a new tool to treat cancerCancer Treatment Reviews, 2004
- Epigenetics in human disease and prospects for epigenetic therapyNature, 2004
- Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignanciesBlood, 2004
- The history of cancer epigeneticsNature Reviews Cancer, 2004
- The power and the promise of DNA methylation markersNature Reviews Cancer, 2003
- In Vivo Activation of cAMP Signaling Induces Growth Arrest and Differentiation in Acute Promyelocytic LeukemiaJournal of Experimental Medicine, 2002
- Molecular genetics of human leukemias: New insights into therapySeminars in Hematology, 2002
- Reciprocal products of chromosomal translocations in human cancer pathogenesis: key players or innocent bystanders?Trends in Molecular Medicine, 2002
- Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription FactorScience, 2002
- The language of covalent histone modificationsNature, 2000